Drug Approval | January 20, 2022
VFMCRP receives EU approval for Tavneos for the treatment of ANCA-associated vasculitis
First launches expected in H1 2022
First launches expected in H1 2022
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
This is the company’s first partnership arrangement in China
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
The tele-heath market in India is expected to touch US $ 5.4 billion by 2025 and the adoption of tele-health has accelerated with the onset of Covid-19 in 2020. We caught up with Jeya Kumar, Founder and MD, RaphaCure, a prominent player in this segment and he outlined the opportunities that lie ahead for this segment
Three Indian firms namely Curisin, Immunidex and Telemedicine Indian company are part of the first phase
It is the first monoclonal antibody drug for use in any animal species
Subscribe To Our Newsletter & Stay Updated
